ROIV - Roivant Sciences: Cashing In On Vants And Ventures

2024-04-24 15:15:35 ET

Summary

• Roivant Sciences sold a subsidiary for $7.1 billion and plans a $1.5 billion stock buyback.
• Its pipeline includes promising drugs like IMVT-1402, despite some clinical risks.
• Financially, Roivant is well-capitalized with $6.67 billion in cash against minimal liabilities.
• Investment recommendation: Buy Roivant as part of a high-risk segment of a diversified portfolio.

Roivant Sciences: Strategic Moves and Diverse Pipeline

Roivant Sciences ( ROIV ) is down nearly 5% since my last update in September. Back then, I highlighted the company's strong balance sheet and opportunity in dermatology. Roivant has been quite busy recently....

For further details see: